Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration.

Sponsor
University of Udine
Study ID
NCT06899360
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 120 Years
Healthy Volunteers
Not accepted

Study Details

The VERA-AMD study is a prospective, observational study designed to evaluate clinical progression, prognostic factors, and quality of life in patients with age-related macular degeneration (AMD). The study aims to analyze real-world clinical data to identify key predictors of disease progression and functional outcomes, with the goal of optimizing AMD management. The study involves 200 patients aged ≥50 with a confirmed diagnosis of AMD, monitored through routine clinical practice. Primary outcomes include progression rates to advanced AMD and changes in visual acuity, while secondary outcomes focus on retinal morphology and quality of life. Anti-VEGF therapy and AI-based fluid analysis will be integrated to explore their impact on disease progression and patient outcomes.

Key Dates

First listed
Mar 27, 2025
Start date
Oct 1, 2024
Status verified
Mar 2025
Primary completion
Oct 1, 2026
Completion
Oct 1, 2029

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Observational cohort of patients with age-related macular degeneration
    Observational cohort of patients with age-related macular degeneration eventually receiving anti-VEGF agents as per clinical practice.

Primary Outcome Measure

Best-corrected visual acuity (BCVA) [ Time Frame: through study completion, 36 months ]

Central Contacts

Find similar trials

Nationwide
Age-related macular degeneration trialsOphthalmology trialsRetina trials

Related Studies